A Phase 1 interventional study of Axitinib (AG-013736) in Neoplasms, sponsored by Pfizer. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-05-23.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 6 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Axitinib (AG-013736)
Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
Single Dose: Maximum Observed Plasma Concentration (Cmax)
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose
Area Under the Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf)
AUCinf is obtained from AUC (0 - t) plus AUC (t - infinity).
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose
Single Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose
Single Dose: Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose
Multiple Dose: Maximum Observed Plasma Concentration (Cmax)
Cmax at multiple dosing
Time frame: Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose
Multiple Dose: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
The dosing interval was 12 hours in this study.
Time frame: Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose
Multiple Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tmax at multiple dosing
Time frame: Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose
Multiple Dose: Accumulation Ratio for Cmax (Rac Cmax) and Accumulation Ratio for AUCtau (Rac AUCtau)
Rac Cmax is obtained from Cmax (Cycle 1, Day 15) divided by Cmax (Cycle 1, Day 1) Rac AUCtau is obtained from AUCtau (Cycle 1, Day 15) divided by AUCtau (Cycle 1, Day 1)
Time frame: Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose
Percent Change From Baseline in Soluble Vascular Endothelial Growth Factor Receptor 1, 2, and 3 (s-VEGFR1, s-VEGFR2 and s-VEGFR3), Vascular Endothelial Growth Factor (VEGF), Soluble Stem Cell Factor Receptor (s-KIT )
Percent change from baseline is obtained from (observed value minus baseline value) divided by baseline value multiplied by 100 in each parameter, i.e., s-VEGFR1, VEGFR2, s-VEGFR3, s-KIT, and VEGF
Time frame: Prior to the initial dose (baseline) and Day 1 of Cycle 2
Number of Participants With Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progression of Disease (PD) According to the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)
CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as PD being demonstrated during the first 8 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.
Time frame: Up to 470 days
Number of Participants With Adverse Events
Number of participants with any adverse events, adverse events graded as Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grade 3 or higher , serious adverse events, and adverse events resulted in discontinuation.
Time frame: Up to 470 days of treatment plus 28-days follow-up
| Milestone | AG-013736 |
|---|---|
| Started | 6 |
| Completed | 0 |
| Not completed | 6 |
| Withdrew: Lack of efficacy | 6 |
| ng/mL | AG-013736 |
|---|---|
| 5 mg Single Dose | 20.732 ± 14.492 |
| 7 mg Single Dose | 32.007 ± 28.223 |
| 10 mg Single Dose | 53.123 ± 60.921 |
AUCinf is obtained from AUC (0 - t) plus AUC (t - infinity).
| ng*hr/mL | AG-013736 |
|---|---|
| 5 mg Single Dose | 180.25 ± 154.90 |
| 7 mg Single Dose | 228.45 ± 183.12 |
| 10 mg Single Dose | 379.12 ± 345.50 |
| hours | AG-013736 |
|---|---|
| 5 mg Single Dose | 4.1000 (3.950 to 6.020) |
| 7 mg Single Dose | 4.0000 (0.983 to 9.880) |
| 10 mg Single Dose | 4.0150 (2.050 to 6.000) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hours | AG-013736 |
|---|---|
| 5 mg Single Dose | 4.778 ± 2.815 |
| 7 mg Single Dose | 5.088 ± 2.592 |
| 10 mg Single Dose | 5.880 ± 3.456 |
Cmax at multiple dosing
| ng/mL | AG-013736 |
|---|---|
| Multiple Dose: Maximum Observed Plasma Concentration (Cmax) | 25.933 ± 21.703 |
The dosing interval was 12 hours in this study.
| ng*h/mL | AG-013736 |
|---|---|
| Multiple Dose: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) | 164.55 ± 128.15 |
Tmax at multiple dosing
| hours | AG-013736 |
|---|---|
| Multiple Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax) | 4.0400 (3.930 to 7.700) |
Rac Cmax is obtained from Cmax (Cycle 1, Day 15) divided by Cmax (Cycle 1, Day 1) Rac AUCtau is obtained from AUCtau (Cycle 1, Day 15) divided by AUCtau (Cycle 1, Day 1)
| ratio | AG-013736 |
|---|---|
| Rac Cmax | 1.3540 ± 0.5335 |
| Rac AUCtau | 1.4185 ± 0.3951 |
Percent change from baseline is obtained from (observed value minus baseline value) divided by baseline value multiplied by 100 in each parameter, i.e., s-VEGFR1, VEGFR2, s-VEGFR3, s-KIT, and VEGF
| percent | AG-013736 |
|---|---|
| s-VEGFR1 | -29.15 (-31.4 to -25.3) |
| s-VEGFR2 | -33.16 (-58.4 to -26.2) |
| s-VEGFR3 | -56.38 (-66.2 to -42.1) |
| s-KIT | -14.59 (-23.7 to -5.2) |
| VEGF | 179.52 (37.0 to 1444.6) |
CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as PD being demonstrated during the first 8 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.
| participants | AG-013736 |
|---|---|
| CR | 0 |
| PR | 0 |
| SD | 3 |
| PD | 3 |
Number of participants with any adverse events, adverse events graded as Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grade 3 or higher , serious adverse events, and adverse events resulted in discontinuation.
| participants | AG-013736 |
|---|---|
| Any adverse events | 6 |
| Any serious adverse events | 1 |
| Any Grade-3 or -4 adverse events | 4 |
| Any Grade-5 adverse events (= death) | 1 |
| Discontinuation due to adverse events | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AG-013736 | — | 1/6 (16.7%) | 6/6 (100%) |
| Event | AG-013736 |
|---|---|
| Disease progressionGeneral disorders | 1/6 |
| Event | AG-013736 |
|---|---|
| FatigueGeneral disorders | 5/6 |
| HypertensionVascular disorders | 5/6 |
| Blood thyroid stimulating hormone increasedInvestigations | 4/6 |
| ProteinuriaRenal and urinary disorders | 4/6 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 4/6 |
| DiarrhoeaGastrointestinal disorders | 3/6 |
| Blood alkaline phosphatase increasedInvestigations | 3/6 |
| Blood amylase increasedInvestigations | 3/6 |
| Blood lactate dehydrogenase increasedInvestigations | 3/6 |
| Decreased appetiteMetabolism and nutrition disorders | 3/6 |
| Age Continuous(years) | AG-013736 |
|---|---|
| Mean | 53.8 ± 15.8 |
| Sex: Female, Male(Participants) | AG-013736 |
|---|---|
| Female | 3 |
| Male | 3 |
The record gives a start of Jul 2008, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib